Stolz Brian M. - Insider Trading Tracker

BridgeBio Pharma, Inc.

US ˙ NasdaqGS ˙ US10806X1028

Introduction

This page provides a comprehensive analysis of the known insider trading history of Stolz Brian M.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

See Highest Ranking Insiders

Companies with Reported Insider Positions

The SEC filings indicate Stolz Brian M. has reported holdings or trades in the following companies:

Security	Title	Latest Reported Holdings
US:BBIO / BridgeBio Pharma, Inc.	Chief Operating Officer	23,937
US:ATVI / Activision Blizzard Inc		44,948
US:BHC / Bausch Health Companies Inc.	EVP, Administration & CHCO	125,280

How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Stolz Brian M.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases BBIO / BridgeBio Pharma, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in BBIO / BridgeBio Pharma, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Max	Price at Max	Max Profit ($)	Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

BBIO / BridgeBio Pharma, Inc. Insider Trades

Insider Sales BBIO / BridgeBio Pharma, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in BBIO / BridgeBio Pharma, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Min	Price at Min	Max Loss Avoided ($)	Max Loss Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Insider Purchases BHC / Bausch Health Companies Inc. - Short Term Profit Analysis

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Max	Price at Max	Max Profit ($)	Max Return (%)
2013-08-12	VRX	Stolz Brian M.	4,500	100.7105	4,500	100.7105	453,197	192	148	212,803	46.96
2012-11-07	VRX	Stolz Brian M.	2,040	52.7560	2,040	52.7560	107,622
2012-05-10	VRX	Stolz Brian M.	5,000	53.1013	5,000	53.1013	265,506
2011-08-11	VRX	Stolz Brian M.	1,800	39.2089	1,800	39.2089	70,576
2011-08-09	VRX	Stolz Brian M.	750	39.1006	750	39.1006	29,325

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

BHC / Bausch Health Companies Inc. Insider Trades

Insider Sales BHC / Bausch Health Companies Inc. - Short Term Loss Analysis

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Min	Price at Min	Max Loss Avoided ($)	Max Loss Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Insider Trading History

This table shows the complete list of insider trades made by Stolz Brian M. as disclosed to the Securities Exchange Commission (SEC).

File Date	Tran Date	Form	Ticker	Security	Code	Shares	Remaining Shares	Percent Change	Share Price	Tran Value	Remaining Value
2020-08-18	2020-08-16	4	BBIO	BridgeBio Pharma, Inc. Restricted Stock Units	M - Exercise	-1,595	23,937	-6.25
2020-08-18	2020-08-16	4	BBIO	BridgeBio Pharma, Inc. Common Stock	F - Taxes	-552	24,615	-2.19	28.53	-15,749	702,266
2020-08-18	2020-08-16	4	BBIO	BridgeBio Pharma, Inc. Common Stock	M - Exercise	1,595	25,167	6.77
2020-06-05	2020-06-03	4	BBIO	BridgeBio Pharma, Inc. Restricted Stock Units	A - Award	25,532	25,532
2020-06-05	2020-06-03	4	BBIO	BridgeBio Pharma, Inc. Stock Option (Right to Buy)	A - Award	183,727	183,727
2019-12-16	2019-12-12	4	BBIO	BridgeBio Pharma, Inc. Restricted Stock Units	A - Award	72,696	72,696
2019-11-15	2019-11-13	4	BBIO	BridgeBio Pharma, Inc. Restricted Stock Units	A - Award	106,469	106,469
2019-11-15	2019-11-13	4	BBIO	BridgeBio Pharma, Inc. Stock Option (Right to Buy)	A - Award	102,081	102,081
2019-11-15	2019-11-13	4	BBIO	BridgeBio Pharma, Inc. Common Stock	A - Award	22,839	22,839
2019-08-15	2019-08-13	4	ATVI	Activision Blizzard, Inc. Employee Stock Options	M - Exercise	-134,845	44,948	-75.00
2019-08-15	2019-08-13	4	ATVI	Activision Blizzard, Inc. Common Stock, par value $0.000001 per share	S - Sale	-134,845	108,041	-55.52	47.80	-6,445,267	5,164,101
2019-08-15	2019-08-13	4	ATVI	Activision Blizzard, Inc. Common Stock, par value $0.000001 per share	M - Exercise	134,845	242,886	124.81	40.61	5,476,055	9,863,600
2019-06-03	2019-05-30	4	ATVI	Activision Blizzard, Inc. Common Stock, par value $0.000001 per share	F - Taxes	-36,405	108,041	-25.20	43.56	-1,585,802	4,706,266
2018-11-14	2018-11-12	4	ATVI	Activision Blizzard, Inc. Common Stock, par value $0.000001 per share	A - Award	11,598	157,120	7.97
2017-11-08	2017-11-06	4	ATVI	Activision Blizzard, Inc. Common Stock, par value $0.000001 per share	A - Award	10,268	145,522	7.59
2016-11-09	2016-11-07	4	ATVI	Activision Blizzard, Inc. Common Stock, par value $0.000001 per share	A - Award	15,210	135,254	12.67
2016-08-10	2016-08-08	4	ATVI	Activision Blizzard, Inc. Employee Stock Options	A - Award	179,793	179,793
2016-08-10	2016-08-08	4	ATVI	Activision Blizzard, Inc. Common Stock, par value $0.000001 per share	A - Award	120,044	120,044
2015-06-24	2015-06-22	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	F - Taxes	2,292	125,280	1.86
2015-05-05	2015-05-01	4	VRX	Valeant Pharmaceuticals International, Inc. Restricted Share Units	M - Exercise	-3,675	0	-100.00
2015-05-05	2015-05-01	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	F - Taxes	-1,921	94,139	-2.00
2015-05-05	2015-05-01	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	M - Exercise	3,675	96,060	3.98
2015-01-28	2015-01-26	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	F - Taxes	-760	92,385	-0.82
2015-01-26	2015-01-22	4	VRX	Valeant Pharmaceuticals International, Inc. Restricted Share Units	M - Exercise	-7,350	3,675	-66.67
2015-01-26	2015-01-22	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	F - Taxes	-2,789	93,145	-2.91
2015-01-26	2015-01-22	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	M - Exercise	7,350	95,934	8.30
2014-12-24	2014-12-23	4	VRX	Valeant Pharmaceuticals International, Inc. Restricted Share Units	M - Exercise	-15,426	33,433	-31.57
2014-12-24	2014-12-23	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	F - Taxes	-8,034	88,584	-8.32
2014-12-24	2014-12-23	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	M - Exercise	15,426	96,618	19.00
2014-10-30	2014-10-28	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	F - Taxes	-908	81,192	-1.11
2014-10-27	2014-10-23	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	F - Taxes	-784	82,100	-0.95
2014-10-14	2014-10-10	4	VRX	Valeant Pharmaceuticals International, Inc. Restricted Share Units	M - Exercise	-3,675	11,025	-25.00
2014-10-14	2014-10-10	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	F - Taxes	-1,907	82,884	-2.25
2014-10-14	2014-10-10	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	M - Exercise	3,675	84,791	4.53
2014-10-02	2014-09-30	4	VRX	Valeant Pharmaceuticals International, Inc. Restricted Share Units	M - Exercise	-23,030	45,000	-33.85
2014-10-02	2014-09-30	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	F - Taxes	-11,948	81,116	-12.84
2014-10-02	2014-09-30	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	M - Exercise	23,030	93,064	32.88
2014-08-07	2014-08-06	4	VRX	Valeant Pharmaceuticals International, Inc. Restricted Share Units	M - Exercise	-18,111	45,000	-28.70
2014-08-07	2014-08-06	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	F - Taxes	-9,397	70,034	-11.83
2014-08-07	2014-08-06	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	M - Exercise	18,111	79,431	29.54
2014-07-23	2014-07-23	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	F - Taxes	-867	61,320	-1.39
2014-02-12	2014-02-11	4	VRX	Valeant Pharmaceuticals International, Inc. Restricted Share Units	M - Exercise	-14,700	14,700	-50.00
2014-02-12	2014-02-11	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	F - Taxes	-7,596	62,187	-10.89
2014-02-12	2014-02-11	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	M - Exercise	14,700	69,783	26.69
2014-01-22	2014-01-20	4	VRX	Valeant Pharmaceuticals International, Inc. Restricted Share Units	M - Exercise	-45,000	45,000	-50.00
2014-01-22	2014-01-20	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	F - Taxes	-243	55,083	-0.44
2014-01-22	2014-01-20	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	F - Taxes	-332	55,326	-0.60
2014-01-22	2014-01-20	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock,no par value	F - Taxes	-22,281	55,658	-28.59
2014-01-22	2014-01-20	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	M - Exercise	45,000	77,939	136.62
2013-10-28	2013-10-24	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	F - Taxes	-892	42,939	-2.04
2013-10-22	2013-10-20	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	A - Award	4,500	43,831	11.44
2013-08-21	2013-08-21	4	VRX	Valeant Pharmaceuticals International, Inc. Restricted Share Units	M - Exercise	-14,700	14,700	-50.00
2013-08-21	2013-08-21	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par values	F - Taxes	-7,525	39,331	-16.06
2013-08-21	2013-08-21	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par values	M - Exercise	14,700	46,856	45.71
2013-08-12	2013-08-12	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	P - Purchase	4,500	32,156	16.27	100.71	453,197	3,238,447
2013-07-23	2013-07-20	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	F - Taxes	-687	27,656	-2.42
2013-01-22	2013-01-20	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	F - Taxes	-347	28,343	-1.21
2013-01-22	2012-01-20	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	A - Award	2,040	28,690	7.65
2012-11-08	2012-11-07	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	P - Purchase	2,040	26,650	8.29	52.76	107,622	1,405,947
2012-10-26	2012-10-24	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	F - Taxes	-650	24,610	-2.57
2012-07-24	2012-07-20	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	A - Award	5,000	25,260	24.68
2012-05-14	2012-05-10	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	P - Purchase	5,000	20,260	32.77	53.10	265,506	1,075,832
2012-01-24	2012-01-20	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	A - Award	2,400	15,260	18.66
2011-08-11	2011-08-11	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	P - Purchase	1,800	2,550	240.00	39.21	70,576	99,983
2011-08-11	2011-08-09	4	VRX	Valeant Pharmaceuticals International, Inc. Common Stock, no par value	P - Purchase	750	750		39.10	29,325	29,325

Open market or private purchase of non-derivative or derivative security

Open market or private sale of non-derivative or derivative security

Grant, award, or other acquisition of securities from the company (such as an option)

Conversion of derivative

Sale or transfer of securities back to the company

Payment of exercise price or tax liability using portion of securities received from the company

Gift of securities by or to the insider

Equity swaps and similar hedging transactions

Exercise or conversion of derivative security received from the company (such as an option)

A transaction voluntarily reported on Form 4

Other (accompanied by a footnote describing the transaction)